ArticleGeburtshilfe und Frauenheilkunde2013
Epidemiology of Malignant Cervical, Corpus Uteri and Ovarian Tumours - Current Data and Epidemiological Trends.
Article in Geburtshilfe und Frauenheilkunde, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 44 citations in OpenAlex.
- Macrophage capping protein CapG is a putative oncogene involved in migration and invasiveness in ovarian carcinoma.BioMed research international · 2014Trial
- Article
- Collagen type IV alpha 6 promotes tumor progression and chemoresistance in ovarian cancer by activating the discoidin domain receptor 1 pathway.Oncogenesis · 2025Article
- Association between gynecologic cancer and Alzheimer's disease: a bidirectional mendelian randomization study.BMC cancer · 2024Article
- A histopathological review of gynaecological malignancies in Katsina state North-Western Nigeria.Ecancermedicalscience · 2024Article
- circDENND4C, a novel serum marker for epithelial ovarian cancer, acts as a tumor suppressor by downregulating miR-200b/c.Annals of medicine · 2023Article
- circ_0025033 promotes ovarian cancer development via regulating the hsa_miR-370-3p/SLC1A5 axis.Cellular & molecular biology letters · 2022Article
- Integration of Transcriptome and Epigenome to Identify and Develop Prognostic Markers for Ovarian Cancer.Journal of oncology · 2022Article
- Identification of solute-carrier family 27A molecules (SCL27As) as a potential biomarker of ovarian cancer based on bioinformatics and experiments.Annals of translational medicine · 2021Article
- Identification of a Novel Tumor Microenvironment Prognostic Signature for Advanced-Stage Serous Ovarian Cancer.Cancers · 2021Article
- Research Progress on the Functions and Mechanism of circRNA in Cisplatin Resistance in Tumors.Frontiers in pharmacology · 2021Review
- Development and Validation of a Novel 11-Gene Prognostic Model for Serous Ovarian Carcinomas Based on Lipid Metabolism Expression Profile.International journal of molecular sciences · 2020Article
- Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment.Frontiers in pharmacology · 2020Article
- The emerging roles of circular RNAs in ovarian cancer.Cancer cell international · 2020Review
- Circular RNA Cdr1as Upregulates SCAI to Suppress Cisplatin Resistance in Ovarian Cancer via miR-1270 Suppression.Molecular therapy. Nucleic acids · 2019Article
- Incidence and mortality of corpus uteri cancer in China, 2008Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2019Article
- Systematic characterization of germline variants from the DiscovEHR study endometrial carcinoma population.BMC medical genomics · 2019Article
- Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression.Cell death & disease · 2019Article
- Anti-cancer effects of Kaempferia parviflora on ovarian cancer SKOV3 cells.BMC complementary and alternative medicine · 2018Article
- Impact of DNA and RNA Methylation on Radiobiology and Cancer Progression.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical, uterine and ovarian cancers are the most common malignancies of the female genital tract. Using current data from population-based cancer registries in Germany, we present the recent figures for the incidence, prevalence, associated mortality and survival for these cancers. In 2009, a total of 23 800 women were newly diagnosed with one of the three gynaecological cancers (cervical cancer: 20.3 %, endometrial cancer: 48.5 %, ovarian cancer: 31.2 %). This figure equals approximately one third of the number of women newly diagnosed with breast cancer in the same year. The relative 5-year survival for carcinomas of the corpus uteri is 79 % and is higher that those for cervical cancer (68 %) and ovarian cancer (40 %). Ovarian cancer in particular is often diagnosed at a later stage and has a high risk of recurrence. Due to the favourable prognosis for endometrial tumours and the unfavourable prognosis for ovarian malignancies, the incidence of various gynaecological tumours is ranked differently compared to the 5-year prevalence of these same tumours. Currently, the 5-year prevalence in Germany for patients with cervical, endometrial or ovarian cancer is estimated to be around 80 000 women. Slightly more than half of these women were diagnosed with cancer of the corpus uteri. Around 25 % of women have ovarian and 21 % have cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.